Study Summary
This trial looks at how well a drug called ruxolitinib works in treating patients with a condition called hypereosinophilic syndrome or another condition called primary eosinophilic disorders.
- Hypereosinophilic Syndrome
- Chronic Eosinophilic Leukemia, Not Otherwise Specified
- Leukemia
- JAK2 Gene Mutation
- Aplastic Anemia
- Enlarged Spleen
- TEL-JAK2 Fusion Protein Expression
- Eosinophilia
- BCR-JAK2 Fusion Protein Expression
- Enlarged Liver
- Bone Marrow Blast Count
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 7 Secondary · Reporting Duration: 3 years
Trial Safety
Safety Progress
Side Effects for
Trial Design
1 Treatment Group
Treatment (ruxolitinib)
1 of 1
Experimental Treatment
25 Total Participants · 1 Treatment Group
Primary Treatment: Ruxolitinib · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What maladies has Ruxolitinib been commonly utilized to treat?
"Patients suffering from polycythemia vera, polycythemia, or hydroxyurea-resistant/intolerant conditions can be treated with Ruxolitinib." - Anonymous Online Contributor
Are there remaining vacancies in this clinical trial?
"According to information hosted on clinicaltrials.gov, this research is open for recruitment of patients at the moment of writing. The trial was initially posted in November 15th 2019 with its latest update being made October 5th 2022." - Anonymous Online Contributor
Are there any other experiments that have used Ruxolitinib for research?
"Ruxolitinib was initially examined in 2002 at the National Institutes of Health Clinical Center located on Rockville Pike. Since then, 93 studies have been concluded and 97 are currently active with many being conducted from Salt Lake City, Utah." - Anonymous Online Contributor
At how many locations is the experiment being conducted?
"This clinical trial is available in 4 distinct locations, such as the University of Utah at Salt Lake City, OHSU Knight Cancer Institute in Portland and Stanford Cancer Institute Palo Alto." - Anonymous Online Contributor
How many individuals have enrolled in this clinical investigation?
"25 people who meet the listed requirements are needed to take part in this research. Patients may join either at University of Utah, Salt Lake City or OHSU Knight Cancer Institute, Portland (Oregon)." - Anonymous Online Contributor
Is Ruxolitinib a risk-free medication for human consumption?
"Considering the Phase 2 status of this trial, which entails limited evidence in terms of safety but none for efficacy, Power gave ruxolitinib a score of two on its risk assessment scale." - Anonymous Online Contributor